RYTHM (RYM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Aug, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Central Time on August 10, 2026, with management and board members present.
Agenda and rules for orderly conduct were outlined, with instructions for stockholder participation and question submission.
Meeting held pursuant to notice dated July 9, 2026, with only stockholders of record as of June 26, 2026, eligible to vote.
Shareholder proposals
Proposal presented to approve issuance of common stock to holders of certain convertible promissory notes and warrants, and pursuant to shared services agreements, in accordance with Nasdaq Listing Rule 5635.
Stockholders could vote for, against, or abstain on the proposal.
Overview of voting outcomes
Quorum established with over one-third of shares represented by proxy.
Proposal passed by the requisite majority of votes cast.
Vote totals to be reported on Form 8-K filed with the SEC.
Latest events from RYTHM
- Revenue and profitability soared on licensing and beverage growth, but regulatory risks persist.RYM
Q2 2026 - Shareholders will vote on issuing shares that could give Green Thumb Industries over 90% control.RYM
Proxy filing - Shareholders will vote on a proposal that could give Green Thumb Industries over 90% control.RYM
Proxy filing - All proposals passed as the company targets THC market growth with strong brands and zero debt.RYM
AGM 2026 - Rising THC demand, regulatory shifts, and strong licensing revenue drive growth and market reach.RYM
Investor presentation - Q1 2026 net income $19.9M, 78% margin, revenue $13.3M, Q2 outlook $22M, strong licensing growth.RYM
Q1 2026 - Virtual meeting to elect directors, ratify auditor, and expand equity plan on June 16, 2026.RYM
Proxy filing - Annual meeting to elect directors, ratify auditor, and expand equity plan; Green Thumb holds 50%.RYM
Proxy filing - Q4 revenue up 164% with 75% gross margin; regulatory risks persist for hemp-derived THC.RYM
Q4 2025